Pancreatic cancer is among the deadliest cancers. A new drug being tested at Penn is giving patients and doctors hope
PHILADELPHIA — Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to stage 4 less than a year after her initial diagnosis. A new drug being tested in clinical trials around the world, including at Penn Medicine’s Abramson Cancer Center, was the 59-year-old grandmother from Newark, Del.’s best hope for more time. The drug ...